OneSource Specialty Pharma Limited has reported a strong recovery for the quarter ended March 31, 2026. Driven by the successful commercial launch of semaglutide in India and expansion across its injectables and soft-gelatin business units, the company saw revenue rise by 47% on a quarterly basis. With EBITDA growing over fivefold sequentially, the firm has reaffirmed its commitment to its long-term financial guidance for the 2028 fiscal year.
Quarterly Financial Highlights
OneSource delivered a robust performance in Q4FY26 (Jan-Mar 2026), reporting revenue of ₹4,282 million, a 47% increase compared to the previous quarter. The company’s EBITDA reached ₹919 million, reflecting a more than 5x increase quarter-on-quarter as margins expanded by 1550 basis points to 21%. Adjusted profit after tax stood at ₹390 million, marking a significant turnaround from the losses recorded in the prior quarter.
Strategic Growth Drivers
The company’s strong performance is attributed to broad-based momentum across its service offerings. Key highlights include the successful Day-1 India launch of semaglutide through multiple partners and new product introductions in the US injectables and soft-gelatin markets. Notably, OneSource has secured the first generic semaglutide approvals in Canada and maintains a record-high biologics funnel. The company also reported 10+ new licensing deals and 15+ commercial product launches during the fiscal year.
Operational Progress and Outlook
OneSource is actively expanding its manufacturing capacity, with approximately $80 million committed to date toward a $100 million capex program at its flagship facility. The company has reaffirmed its FY28 guidance, targeting $400 million in organic revenue and a steady-state EBITDA margin of ~40%. Additionally, the company has opted to pause its proposed acquisition of specialty injectable assets from Steriscience to focus on delivering its current strategic objectives and will consider re-engaging post-FY28.
Regulatory and Compliance Success
The company maintains a strong track record of quality, evidenced by 49 successful regulatory inspections and customer audits during the fiscal year with zero critical observations. Key regulatory milestones include the receipt of the USFDA Establishment Inspection Report (EIR) for its flagship site and renewed EU-GMP certification, ensuring continued global market access for its product portfolio.
Source: BSE
